Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans
- 21 January 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (833) , eady2646
Abstract
Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO 300 ) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO 300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO 300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO 300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO 300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.Keywords
Funding Information
- National Institutes of Health (R01 GM148664)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK034854)
- Massachusetts General Hospital (Philanthropy at the Lung Rescue Team)
- Harvard Medical School (Reginald Jenney Endowment Chair at Harvard Medical School)
- Mallinckrodt Pharmaceuticals (2024A015231)
- Masimo (2023A008593)
This publication has 53 references indexed in Scilit:
- Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patientsThe American Journal of Emergency Medicine, 2022
- Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumoniaNitric Oxide, 2021
- Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclaseJournal of Biological Chemistry, 2021
- Ideation and assessment of a nitric oxide delivery system for spontaneously breathing subjectsNitric Oxide, 2020
- Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infectionJournal of Cystic Fibrosis, 2020
- Pharmacological preconditioning with inhaled nitric oxide (NO): Organ-specific differences in the lifetime of blood and tissue NO metabolitesNitric Oxide, 2018
- Development of a portable mini-generator to safely produce nitric oxide for the treatment of infants with pulmonary hypertensionNitric Oxide, 2018
- Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical studyInfection, 2016
- Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumoniaJournal of Cystic Fibrosis, 2013
- A phase I clinical study of inhaled nitric oxide in healthy adultsJournal of Cystic Fibrosis, 2012